Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022137 | 0.89 | NR1H4 (0.54) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL161921 | 0.89 | SMN1; SMN2 (0.55) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL158877 | 0.85 | TRPV1 (0.49) | NPC1RAB9AMEN1KMT2AHDAC6 | |
| SCHEMBL160613 | 0.83 | PTPN1 (0.50) | PTPN1NR1H4CSNK2A2CSNK2A1DEGS1 | |
| SCHEMBL159199 | 0.81 | MEN1 (0.52) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL160757 | 0.80 | NR1H4 (0.67) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL160976 | 0.79 | SMN1; SMN2 (0.51) | NPC1RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL161099 | 0.78 | GLS (0.46) | NPC1RAB9AKMT2ACSNK2A2CSNK2A1 | |
| SCHEMBL161606 | 0.77 | TRPV1 (0.50) | MEN1KMT2AHDAC6NR1H4SMN1; SMN2 | |
| SCHEMBL164156 | 0.75 | MAPT (0.52) | RXFP1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | RXFP1 4452/4885NPC1 86/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.